• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tharimmune, Inc. - Common Stock (NQ: THAR )

    0.3761 -0.0340 (-8.29%)
    Streaming Delayed Price Updated: 3:59 PM EDT, May 10, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 354,777
    Open 0.4110
    Bid (Size) 0.3701 (5)
    Ask (Size) 0.3800 (3)
    Prev. Close 0.4101
    Today's Range 0.3630 - 0.4199
    52wk Range 0.1434 - 4.790
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    THAR Stock Earnings: Tharimmune Reported Results for Q4 2023
    Tharimmune just reported results for the fourth quarter of 2023. 
    Via InvestorPlace
    Tharimmune To Participate in Two Upcoming Investor Conferences in May
    Via ACCESSWIRE

    Performance

    YTD
    -25.51%
    -25.51%
    1 Month
    -8.93%
    -8.93%
    3 Month
    -2.31%
    -2.31%
    6 Month
    +105.63%
    +105.63%
    1 Year
    +70.88%
    +70.88%

    More News

    Read More
    Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
    Via ACCESSWIRE
    Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
    Via ACCESSWIRE
    Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
    Via ACCESSWIRE
    Tharimmune's Oral 'Under The Cheek' Candidate At Par With FDA-Approved Injectable With Potential For Chronic Liver Disease
    Via Benzinga
    Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
    Via ACCESSWIRE
    Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Perspective Therapeutics And 3 Other Stocks Under $1 Insiders Are Buying
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
    Via ACCESSWIRE
    Why Hello Group Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Tharimmune, Inc. Announces Closing of $11 Million Public Offering
    Via ACCESSWIRE
    Stonegate Healthcare Partners Releases Report on Transformative Therapies for Pruritus Management
    Via Newsfile
    BioMedNewsBreaks – Tharimmune Inc. (NASDAQ: THAR) Announces Pricing of $10M Public Offering
    Via Investor Brand Network
    Crude Oil Surges 2%; Tharimmune Shares Plummet
    Via Benzinga
    Topics Stocks
    Exposures Fossil Fuels US Equities
    Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    Why Tharimmune Stock (THAR) Is Down 70% Today
    Via Benzinga
    Shein IPO Alert: 7 Things for Potential Shein Stock Investors to Know
    Via InvestorPlace
    Topics Initial Public Offering
    Exposures Securities Market
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.